$Ocugen(OCGN.US)$Ocugen Says It Will Present On Modifier Gene Therapy Platform At Association For Research In Vision And Ophthalmology 2024 Annual Meeting
$Ocugen(OCGN.US)$Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
$Ocugen(OCGN.US)$ Ocugen (NASDAQ:OCGN) shares traded higher on Wednesday after the company said that EU regulators agreed to a U.S.-based trial to support a marketing authorization application for the company’s gene therapy candidate, OCU400. The decision comes after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), reviewed the critical components of the company's Phase 3 liMeliGhT clinical trial for OCU400...
$Ocugen(OCGN.US)$Ocugen Disclosed Positive Scientific Advice From The European Medicines Agency Related To The Approval Pathway For Ocu400—Modifier Gene Therapy For Broad Retinitis Pigmentosa Indication
$Ocugen(OCGN.US)$Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication 4 MINUTES AGO, 6:30 AM EDT VIA GLOBENEWSWIRE
A New Dawn in the Treatment of Geographic Atrophy: Ocugen's OCU410 Shows Promising Early Results. In a landmark announcement on April 5, 2024, Ocugen, Inc., a pioneer in gene and cell therapies, has taken a significant step forward in the fight against Geographic Atrophy (GA), a severe form of age-related macular degeneration that leads to blindness. The Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaD...
Ocugen股票討論區
What comes outa this?
new rating
Update
ROCKET🚀🚀🚀Ocugen says EU backs a U.S. trial for gene therapy
Ocugen (NASDAQ:OCGN) shares traded higher on Wednesday after the company said that EU regulators agreed to a U.S.-based trial to support a marketing authorization application for the company’s gene therapy candidate, OCU400.
The decision comes after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), reviewed the critical components of the company's Phase 3 liMeliGhT clinical trial for OCU400...
Update! Hopefully soon?
Update
4 MINUTES AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Gene Therapy Company Announces Positive Results For Geographic Atrophy Treatment
In a landmark announcement on April 5, 2024, Ocugen, Inc., a pioneer in gene and cell therapies, has taken a significant step forward in the fight against Geographic Atrophy (GA), a severe form of age-related macular degeneration that leads to blindness. The Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaD...
Took Profits
暫無評論